tiprankstipranks
NightHawk Biosciences (NHWK)
NYSE MKT:NHWK

NightHawk Biosciences Stock Analysis & Ratings

NHWK Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.60 - $7.63
Previous Close$2.58
Volume54.04K
Average Volume (3M)123.51K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-1.8
Beta0.47
Next EarningsAug 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NHWK FAQ

What was NightHawk Biosciences’s price range in the past 12 months?
NightHawk Biosciences lowest stock price was $1.60 and its highest was $7.63 in the past 12 months.
    What is NightHawk Biosciences’s market cap?
    Currently, no data Available
    What is NightHawk Biosciences’s price target?
    The average price target for NightHawk Biosciences is $8.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 193.04% Increase from the current price of $2.73.
      What do analysts say about NightHawk Biosciences?
      NightHawk Biosciences’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is NightHawk Biosciences’s upcoming earnings report date?
        NightHawk Biosciences’s upcoming earnings report date is Aug 15, 2022 which is in 39 days.
          How were NightHawk Biosciences’s earnings last quarter?
          NightHawk Biosciences released its earnings results on May 16, 2022. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.437 by $0.117.
            Is NightHawk Biosciences overvalued?
            According to Wall Street analysts NightHawk Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does NightHawk Biosciences pay dividends?
              NightHawk Biosciences does not currently pay dividends.
              What is NightHawk Biosciences’s EPS estimate?
              NightHawk Biosciences’s EPS estimate is -$0.3.
                How many shares outstanding does NightHawk Biosciences have?
                NightHawk Biosciences has 25,649,824 shares outstanding.
                  What happened to NightHawk Biosciences’s price movement after its last earnings report?
                  NightHawk Biosciences reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.437. Following the earnings report the stock price went up 10.86%.
                    Which hedge fund is a major shareholder of NightHawk Biosciences?
                    Currently, no hedge funds are holding shares in NHWK

                    ---

                    NightHawk Biosciences Stock Analysis

                    The NightHawk Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    NightHawk Biosciences

                    Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Bristol Myers
                    Merck & Company
                    Pfizer
                    Eli Lilly & Co
                    Chinook Therapeutics

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis